Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

Key Inclusion Criteria: * Individuals must be 18 years of age or older * Must have Myasthenia Gravis Foundation of America (MGFA) clinical classification Grades 2-4A at time of screening * Participant must have clinically active disease and requiring ongoing therapy for Generalized Myasthenia Gravis (GMG) * MG-ADL score ≥ 6 and QMG score ≥ 10 at screening * GMG specific autoantibodies must be above the reference laboratory upper limit of normal (ULN) Key Exclusion Criteria: * Individual is pregnant or breastfeeding * Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion * Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager * Previous thymectomy within 6 months of screening * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator Note: Other protocol defined Inclusion/Exclusion criteria may apply.